NCT07001189 Impact of Regional Anesthesia on Inflammatory Mechanisms During Vaso-occlusive Crisis in Sickle Cell Patients
| NCT ID | NCT07001189 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de la Guadeloupe |
| Condition | Sickle Cell |
| Study Type | OBSERVATIONAL |
| Enrollment | 34 participants |
| Start Date | 2025-02-05 |
| Primary Completion | 2027-02-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 34 participants in total. It began in 2025-02-05 with a primary completion date of 2027-02-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Sickle cell disease is a chronic disease characterized by multiple vaso-occlusive complications. The basic treatment for patients with a vaso-occlusive crisis (VOC) is based on adequate hydration, oxygen therapy and pain control. Loco Regional Anesthesia (LRA) is one of the major treatments in resuscitation anesthesia for both anesthesia and analgesia. LRA allows effective and almost immediate pain control by blocking nerve afferents in a given area. LRA could decrease the inflammatory response during crises and accelerate resolution of the crisis.
Eligibility Criteria
Inclusion Criteria: * patients adult \>18 years * patients with vaso-occlusive crisis Exclusion Criteria: * Pregnant or breastfeeding women * Blood transfusion within the last 3 months * Lack of affiliation with the French social security system * Protected individuals
Contact & Investigator
Amelie Rolle, MD
PRINCIPAL INVESTIGATOR
CHU de la Guadeloupe
Frequently Asked Questions
Who can join the NCT07001189 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sickle Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07001189 currently recruiting?
Yes, NCT07001189 is actively recruiting participants. Contact the research team at valerie.soter@chu-guadeloupe.fr for enrollment information.
Where is the NCT07001189 trial being conducted?
This trial is being conducted at Pointe-à-Pitre, Guadeloupe.
Who is sponsoring the NCT07001189 clinical trial?
NCT07001189 is sponsored by Centre Hospitalier Universitaire de la Guadeloupe. The principal investigator is Amelie Rolle, MD at CHU de la Guadeloupe. The trial plans to enroll 34 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.